Work

Cell-based Immunotherapy Against Gliomas: From Bench to Bedside

Year: 2013

Type: review

Abstract: Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18-21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate indicates, these treatments have not been effective in preventing disease progression. Cellular immunotherapy is currently being explored as therapeutic approach to treat malignant brain tumors. In this review, we discuss advances in active, passive, and vaccine-based immunotherapeutic strategies for gliomas both at the bench and in the clinic.

Source: Molecular Therapy

DOI: 10.1038/mt.2013.80

Authors: M Sarah S Bovenberg, M Hannah Degeling, Bakhos A Tannous

Institutions: Harvard University, Leiden University Medical Center, Massachusetts General Hospital

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500